Antoni Torres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Antoni Torres has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Santiago Ewig
5 shared publications- Natividad Benito
Universitat Autònoma de Barcelona, Spain; Hospital de la Santa Creu i Sant Pau - Sant Pau Research Institute, Barcelona, Spain; University of Queensland, Brisbane, Australia
3 shared publications Torsten T. Bauer
Hospital Clìnic de Barcelona, Servei de Pneumologia i Cirogía Toracica, Villarroel 170, 08036 Barcelona, Spain
3 shared publicationsA Moreno
Serveis de Bioquímica i Infeccions, Hospital Clínic, Universitat de Barcelona, Spain
2 shared publicationsA Rañó
Unitat de Cures Intensives, Althaia, Xarxa Assistencial de Manresa, Barcelona, Spain
2 shared publicationsAna Rañó
2 shared publications
Latest Publications
- Open Access
Inflammatory response associated with pulmonary complications in non-HIV immunocompromised patients
Background: A study was undertaken to evaluate the local and systemic inflammatory response associated with pulmonary complications in immunocompromised patients and potential implications regarding severity and prognosis. Methods: Levels of different inflammatory mediators were measured in the bronchoalveolar lavage (BAL) fluid and serum on days 1 and 4 after the identification of the pulmonary complication in 127 patients with different immunosuppressive conditions. Results: Pulmonary complications were characterised by a high percentage of neutrophils and increased levels of tumour necrosis factor (TNF)-α, interleukin (IL)-6, IL-8 and IL-10 in the BAL fluid and high serum levels of TNF-α, IL-6, and plasma C-reactive protein (CRP). The inflammatory response was similar in the different groups of immunocompromised patients evaluated. The levels of proinflammatory cytokines were higher in patients with pulmonary infections, particularly those of bacterial aetiology. Patients with a more severe pulmonary infection had a more intense local and systemic inflammatory response. A BAL fluid IL-6 level of >40 pg/ml was an independent predictor of mortality (OR 4.65, 95% CI 1.3 to 16.1), together with a need for mechanical ventilation (OR 13.5, 95% CI 3.2 to 57.3). Patients who died had persistently high levels of CRP on day 4. Conclusions: The evaluation of the inflammatory response, particularly the determination of IL-6 levels in the BAL fluid and CRP in the serum, may be useful for deciding the appropriate management of pulmonary complications in immunocompromised patients.
Open AccessInflammatory response associated with pulmonary complications in non-HIV immunocompromised patients
Background: A study was undertaken to evaluate the local and systemic inflammatory response associated with pulmonary complications in immunocompromised patients and potential implications regarding severity and prognosis. Methods: Levels of different inflammatory mediators were measured in the bronchoalveolar lavage (BAL) fluid and serum on days 1 and 4 after the identification of the pulmonary complication in 127 patients with different immunosuppressive conditions. Results: Pulmonary complications were characterised by a high percentage of neutrophils and increased levels of tumour necrosis factor (TNF)-α, interleukin (IL)-6, IL-8 and IL-10 in the BAL fluid and high serum levels of TNF-α, IL-6, and plasma C-reactive protein (CRP). The inflammatory response was similar in the different groups of immunocompromised patients evaluated. The levels of proinflammatory cytokines were higher in patients with pulmonary infections, particularly those of bacterial aetiology. Patients with a more severe pulmonary infection had a more intense local and systemic inflammatory response. A BAL fluid IL-6 level of >40 pg/ml was an independent predictor of mortality (OR 4.65, 95% CI 1.3 to 16.1), together with a need for mechanical ventilation (OR 13.5, 95% CI 3.2 to 57.3). Patients who died had persistently high levels of CRP on day 4. Conclusions: The evaluation of the inflammatory response, particularly the determination of IL-6 levels in the BAL fluid and CRP in the serum, may be useful for deciding the appropriate management of pulmonary complications in immunocompromised patients.
- Open Access
Validation of predictive rules and indices of severity for community acquired pneumonia
Background: A study was undertaken to validate the modified American Thoracic Society (ATS) rule and two British Thoracic Society (BTS) rules for the prediction of ICU admission and mortality of community acquired pneumonia and to provide a validation of these predictions on the basis of the pneumonia severity index (PSI). Method: Six hundred and ninety six consecutive patients (457 men (66%), mean (SD) age 67.8 (17.1) years, range 18–101) admitted to a tertiary care hospital were studied prospectively. Of these, 116 (16.7%) were admitted to the ICU. Results: The modified ATS rule achieved a sensitivity of 69% (95% CI 50.7 to 77.2), specificity of 97% (95% CI 96.4 to 98.9), positive predictive value of 87% (95% CI 78.3 to 93.1), and negative predictive value of 94% (95% CI 91.8 to 95.8) in predicting admission to the ICU. The corresponding predictive indices for mortality were 94% (95% CI 82.5 to 98.7), 93% (95% CI 90.6 to 94.7), 49% (95% CI 38.2 to 59.7), and 99.5% (95% CI 98.5 to 99.9), respectively. These figures compared favourably with both the BTS rules. The BTS-CURB criteria achieved predictions of pneumonia severity and mortality comparable to the PSI. Conclusions: This study confirms the power of the modified ATS rule to predict severe pneumonia in individual patients. It may be incorporated into current guidelines for the assessment of pneumonia severity. The CURB criteria may be used as an alternative tool to PSI for the detection of low risk patients.
Open AccessValidation of predictive rules and indices of severity for community acquired pneumonia
Background: A study was undertaken to validate the modified American Thoracic Society (ATS) rule and two British Thoracic Society (BTS) rules for the prediction of ICU admission and mortality of community acquired pneumonia and to provide a validation of these predictions on the basis of the pneumonia severity index (PSI). Method: Six hundred and ninety six consecutive patients (457 men (66%), mean (SD) age 67.8 (17.1) years, range 18–101) admitted to a tertiary care hospital were studied prospectively. Of these, 116 (16.7%) were admitted to the ICU. Results: The modified ATS rule achieved a sensitivity of 69% (95% CI 50.7 to 77.2), specificity of 97% (95% CI 96.4 to 98.9), positive predictive value of 87% (95% CI 78.3 to 93.1), and negative predictive value of 94% (95% CI 91.8 to 95.8) in predicting admission to the ICU. The corresponding predictive indices for mortality were 94% (95% CI 82.5 to 98.7), 93% (95% CI 90.6 to 94.7), 49% (95% CI 38.2 to 59.7), and 99.5% (95% CI 98.5 to 99.9), respectively. These figures compared favourably with both the BTS rules. The BTS-CURB criteria achieved predictions of pneumonia severity and mortality comparable to the PSI. Conclusions: This study confirms the power of the modified ATS rule to predict severe pneumonia in individual patients. It may be incorporated into current guidelines for the assessment of pneumonia severity. The CURB criteria may be used as an alternative tool to PSI for the detection of low risk patients.
- Open Access
- 1 January 2004
- Published by Springer Nature in Critical Care
- Vol. 9 (1) , 5-9
Ethics roundtable debate: A patient dies from an ICU-acquired infection related to methicillin-resistant Staphylococcus aureus – how do you defend your case and your team?
- 1 January 2004
- Published by Springer Nature in Critical Care
- Vol. 9 (1) , 5-9
Open AccessEthics roundtable debate: A patient dies from an ICU-acquired infection related to methicillin-resistant Staphylococcus aureus – how do you defend your case and your team?
- 1 January 2003
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 21 (1) , 135-143
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia
Based on recent guidelines for the management of community-acquired pneumonia, this study was designed to evaluate the effectiveness of a new fluoroquinolone compared with standard antimicrobial regimens, in conditions relating as closely as possible to the real world setting.In this study, 564 patients were randomised to either oral moxifloxacin (400 mgo.d.) or to standard oral therapy (amoxicillin 1 gt.i.d.or clarithromycin 500 mgb.i.d.alone or in combination) for up to 14 days using a double-blind procedure. The choice between the three standard regimens was made by the clinician prior to randomisation. Clinical response, quality of life, symptoms, healthcare resources and safety were assessed.In the per-protocol population, clinical success was reported for 201 of 215 (93.5%) and 217 of 231 (93.9%) in the moxifloxacin and standard groups, respectively, at 7–10 days post-therapy. At 28–35 days follow-up, continued clinical cure was observed in 183 of 192 (95.3%) moxifloxacin and 207 of 221 (93.7%) standard groups. Drug-related adverse events were reported in 55 of 274 (20%) moxifloxacin and 86 of 279 (31%) standard patients with diarrhoea >5%.Oral moxifloxacin monotherapy was as effective as, and better tolerated than, optimal antibiotic strategy represented either by mono- or combination therapy (amoxicillin and/or clarithromycin) in community-acquired pneumonia management.
- 1 January 2003
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 21 (1) , 135-143
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia
Based on recent guidelines for the management of community-acquired pneumonia, this study was designed to evaluate the effectiveness of a new fluoroquinolone compared with standard antimicrobial regimens, in conditions relating as closely as possible to the real world setting.In this study, 564 patients were randomised to either oral moxifloxacin (400 mgo.d.) or to standard oral therapy (amoxicillin 1 gt.i.d.or clarithromycin 500 mgb.i.d.alone or in combination) for up to 14 days using a double-blind procedure. The choice between the three standard regimens was made by the clinician prior to randomisation. Clinical response, quality of life, symptoms, healthcare resources and safety were assessed.In the per-protocol population, clinical success was reported for 201 of 215 (93.5%) and 217 of 231 (93.9%) in the moxifloxacin and standard groups, respectively, at 7–10 days post-therapy. At 28–35 days follow-up, continued clinical cure was observed in 183 of 192 (95.3%) moxifloxacin and 207 of 221 (93.7%) standard groups. Drug-related adverse events were reported in 55 of 274 (20%) moxifloxacin and 86 of 279 (31%) standard patients with diarrhoea >5%.Oral moxifloxacin monotherapy was as effective as, and better tolerated than, optimal antibiotic strategy represented either by mono- or combination therapy (amoxicillin and/or clarithromycin) in community-acquired pneumonia management.
- Open Access
- 9 September 2002
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 162 (16) , 1849-1858
Community-Acquired Pneumonia Due to Gram-Negative Bacteria and Pseudomonas aeruginosa
CURRENT GUIDELINES for the management of adult community-acquired pneumonia (CAP) recommend initial empirical antimicrobial treatment.1-3 This approach is based on microbial patterns derived from several large prospective epidemiological series originating from different regions. One of the major areas of debate includes the incidence of gram-negative bacteria (GNB) and Pseudomonas aeruginosa, and, as a result, the need for general coverage of these organisms when designing appropriate empirical antimicrobial treatment strategies. The reported incidences of CAP in the general population have been quite variable, ranging from 0% to 9% for GNB4,5 and 0% to 5% for P aeruginosa.6,7 On the other hand, these pathogens have repeatedly been found to bear an adverse prognostic potential.8 Given these variations and the potentially serious prognosis, it seems useful to determine which patients are at risk for these infections, thereby providing an additional target to ensure the adequacy of antimicrobial treatment and obviating the need for a general antimicrobial coverage of these pathogens in all patients. Previous studies in this field originating from the 1960s and 1970s are largely observational and suffer from flaws such as inhomogeneous patient populations and a lack of advanced statistical analysis; therefore, they hardly form a valid basis for current management recommendations.
- 9 September 2002
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 162 (16) , 1849-1858
Open AccessCommunity-Acquired Pneumonia Due to Gram-Negative Bacteria and Pseudomonas aeruginosa
CURRENT GUIDELINES for the management of adult community-acquired pneumonia (CAP) recommend initial empirical antimicrobial treatment.1-3 This approach is based on microbial patterns derived from several large prospective epidemiological series originating from different regions. One of the major areas of debate includes the incidence of gram-negative bacteria (GNB) and Pseudomonas aeruginosa, and, as a result, the need for general coverage of these organisms when designing appropriate empirical antimicrobial treatment strategies. The reported incidences of CAP in the general population have been quite variable, ranging from 0% to 9% for GNB4,5 and 0% to 5% for P aeruginosa.6,7 On the other hand, these pathogens have repeatedly been found to bear an adverse prognostic potential.8 Given these variations and the potentially serious prognosis, it seems useful to determine which patients are at risk for these infections, thereby providing an additional target to ensure the adequacy of antimicrobial treatment and obviating the need for a general antimicrobial coverage of these pathogens in all patients. Previous studies in this field originating from the 1960s and 1970s are largely observational and suffer from flaws such as inhomogeneous patient populations and a lack of advanced statistical analysis; therefore, they hardly form a valid basis for current management recommendations.
- 24 July 2002
- Vol. 7 (7) , 304-308
Intrapulmonary neutrophil apoptosis in a pig model of pneumonia
Background: Apoptosis and necrosis are two distinct cell death modalities. Polymorphonuclear leukocytes (PMNL) play an important role in pneumonia and little information is available on whether these cells are cleared by necrosis or apoptosis. We therefore compared the proportion of apoptotic PMNL in lung tissues with and without pneumonia. In addition, the association of PMNL apoptosis and mechanical ventilation (MV) was investigated. Methods: Samples obtained from a pig model developed to tracheobronchial stenting were analysed. Pneumonia was induced with that model in 10 animals (white-Landrace piglets, Pittman-Moore or Gottingen minipigs). Animals were sacrificed when clinical parameters of pneumonia became evident and 17 lung samples could be analysed for histologic evidence of pneumonia, growth of micro-organisms, and the apoptotic index (proportion of apoptotic PMNL over all PMNL in a 400-power field). In addition, lung samples (n = 7) from two pigs without stent implantation on mechanically ventilated for more than 48 h were studied. Results: A total of 9/17 samples (53%) showed histologic evidence of pneumonia, 11/17 (65%) had significant bacterial growth (> 103 cfu/g), and 7/17 (41%) fulfilled both criteria. The apoptotic index was not significantly different in samples with and without histologic evidence of pneumonia (pneumonia: 25.3 +/- 6.1% vs. No pneumonia: 25.2 +/- 11.9%; 95% CI: -9.7 - 9.5, p = 0.989) or in samples with and without significant bacterial growth (significant bacterial growth: 23.5 +/- 9.3% vs. No significant bacterial growth: 28.5 +/- 8.2%; 95% CI: -4.6 - 16.7; 1) = 0.284). However, the apoptotic index was higher in samples of pigs, mechanically ventilated for more than 48 h, compared to the stent group (MV: 36.9 +/- 10.7% vs. Stent: 25.2 +/- 9.0%; 95% Cl: -20.5 - -2.9; p = 0.012). Conclusion: In an animal model, the proportion of apoptotic PMNL was not different in lung samples with and without histologic or bacterial pneumonia. However, MV for more than 48 h was associated with a higher proportion of apoptotic PMNL in lung tissue. This study may be helpful for the understanding of the evolution of lung tissue damage induced by bacterial pneumonia and MV.
- 24 July 2002
- Vol. 7 (7) , 304-308
Intrapulmonary neutrophil apoptosis in a pig model of pneumonia
Background: Apoptosis and necrosis are two distinct cell death modalities. Polymorphonuclear leukocytes (PMNL) play an important role in pneumonia and little information is available on whether these cells are cleared by necrosis or apoptosis. We therefore compared the proportion of apoptotic PMNL in lung tissues with and without pneumonia. In addition, the association of PMNL apoptosis and mechanical ventilation (MV) was investigated. Methods: Samples obtained from a pig model developed to tracheobronchial stenting were analysed. Pneumonia was induced with that model in 10 animals (white-Landrace piglets, Pittman-Moore or Gottingen minipigs). Animals were sacrificed when clinical parameters of pneumonia became evident and 17 lung samples could be analysed for histologic evidence of pneumonia, growth of micro-organisms, and the apoptotic index (proportion of apoptotic PMNL over all PMNL in a 400-power field). In addition, lung samples (n = 7) from two pigs without stent implantation on mechanically ventilated for more than 48 h were studied. Results: A total of 9/17 samples (53%) showed histologic evidence of pneumonia, 11/17 (65%) had significant bacterial growth (> 103 cfu/g), and 7/17 (41%) fulfilled both criteria. The apoptotic index was not significantly different in samples with and without histologic evidence of pneumonia (pneumonia: 25.3 +/- 6.1% vs. No pneumonia: 25.2 +/- 11.9%; 95% CI: -9.7 - 9.5, p = 0.989) or in samples with and without significant bacterial growth (significant bacterial growth: 23.5 +/- 9.3% vs. No significant bacterial growth: 28.5 +/- 8.2%; 95% CI: -4.6 - 16.7; 1) = 0.284). However, the apoptotic index was higher in samples of pigs, mechanically ventilated for more than 48 h, compared to the stent group (MV: 36.9 +/- 10.7% vs. Stent: 25.2 +/- 9.0%; 95% Cl: -20.5 - -2.9; p = 0.012). Conclusion: In an animal model, the proportion of apoptotic PMNL was not different in lung samples with and without histologic or bacterial pneumonia. However, MV for more than 48 h was associated with a higher proportion of apoptotic PMNL in lung tissue. This study may be helpful for the understanding of the evolution of lung tissue damage induced by bacterial pneumonia and MV.
- Open Access
Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors
Background: A study was undertaken to investigate the incidence, diagnostic yield of non-invasive and bronchoscopic techniques, and risk factors of airway colonisation in patients with bronchiectasis in a stable clinical situation. Methods: A 2 year prospective study of 77 patients with bronchiectasis in a stable clinical condition was performed in an 800 bed tertiary university hospital. The interventions used were pharyngeal swabs, sputum cultures and quantitative protected specimen brush (PSB) bacterial cultures (cut off point ≥102 cfu/ml) and bronchoalveolar lavage (BAL) (cut off point ≥103 cfu/ml). Results: The incidence of bronchial colonisation with potential pathogenic microorganisms (PPMs) was 64%. The most frequent PPMs isolated were Haemophilus influenzae (55%) and Pseudomonas spp (26%). Resistance to antibiotics was found in 30% of the isolated pathogens. When the sample was appropriate, the operative characteristics of the sputum cultures were similar to those obtained with the PSB taken as a gold standard. Risk factors associated with bronchial colonisation by PPMs in the multivariate analysis were: (1) diagnosis of bronchiectasis before the age of 14 years (odds ratio (OR)=3.92, 95% CI 1.29 to 11.95), (2) forced expiratory volume in 1 second (FEV1) 1 <80% predicted appear to be risk factors for bronchial colonisation with PPMs.
Open AccessBacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors
Background: A study was undertaken to investigate the incidence, diagnostic yield of non-invasive and bronchoscopic techniques, and risk factors of airway colonisation in patients with bronchiectasis in a stable clinical situation. Methods: A 2 year prospective study of 77 patients with bronchiectasis in a stable clinical condition was performed in an 800 bed tertiary university hospital. The interventions used were pharyngeal swabs, sputum cultures and quantitative protected specimen brush (PSB) bacterial cultures (cut off point ≥102 cfu/ml) and bronchoalveolar lavage (BAL) (cut off point ≥103 cfu/ml). Results: The incidence of bronchial colonisation with potential pathogenic microorganisms (PPMs) was 64%. The most frequent PPMs isolated were Haemophilus influenzae (55%) and Pseudomonas spp (26%). Resistance to antibiotics was found in 30% of the isolated pathogens. When the sample was appropriate, the operative characteristics of the sputum cultures were similar to those obtained with the PSB taken as a gold standard. Risk factors associated with bronchial colonisation by PPMs in the multivariate analysis were: (1) diagnosis of bronchiectasis before the age of 14 years (odds ratio (OR)=3.92, 95% CI 1.29 to 11.95), (2) forced expiratory volume in 1 second (FEV1) 1 <80% predicted appear to be risk factors for bronchial colonisation with PPMs.